Replies to post #214 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

JP always sounds like he has a bad virus.

[DewDiligence]

U.S. Market Share of HBV Drugs



My notes (from Oct 2006):

1. Hepsera (the black line on the chart) is the current market leader in Rx’s by a wide margin. This is bullish for IDIX because Tyzeka is a much more efficacious drug than Hepsera (#msg-14364568).

2. As new HBV drugs are launched, they expand the overall market rather than just stealing share from older drugs. This can be seen from the steady uptake of total prescriptions (the indigo line on the chart) during the period in which Baraclude and Hepsera were introduced. Despite being the oldest and least efficacious drug in the class, Epivir/Lamivudine (the red line on the chart) has maintained a near-constant number of prescriptions during the past four years.